|
FET-Protein Fusions as a Marker of Sensitivity to Transcription Inhibitors and Cyclin-Dependent Kinase Inhibitors
This technology seeks to take advantage of members of the FET protein family that are translocated to form fusion oncogenes. This presents an opportunity to use FET-protein fusions as a means of identifying and treating cancer. Combined treatment of Ewing's sarcoma with a transcription inhibitor, such as flavopiridol, increases cellular sensitivity...
Published: 3/12/2024
|
Inventor(s): Matthew Rollins, Jacob Schwartz, Nasiha Ahmed
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Oncology
|
